Human CTLA-4 / CD152 Protein, His Tag
分子別名(Synonym)
CTLA4,CD152
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human CTLA-4, His Tag (CT4-H5229) is expressed from human 293 cells (HEK293). It contains AA Ala 37 - Phe 162 (Accession # P16410-1).
Predicted N-terminus: Ala 37
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 15.4 kDa. The protein migrates as 20-25 kDa under reducing (R) condition (SDS-PAGE) due to different extent glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 6 months under sterile conditions after reconstitution.
背景(Background)
CTLA-4(細(xì)胞毒性T淋巴細(xì)胞抗原4)也稱為CD152(分化簇152),是一種下調(diào)免疫系統(tǒng)的蛋白質(zhì)受體。CTLA4是免疫球蛋白超家族的成員,在輔助T細(xì)胞表面表達(dá),并向T細(xì)胞傳遞抑制信號(hào)。該蛋白質(zhì)包含一個(gè)細(xì)胞外V結(jié)構(gòu)域、一個(gè)跨膜結(jié)構(gòu)域和一個(gè)細(xì)胞質(zhì)尾部。編碼不同異構(gòu)體的替代剪接變體。CTLA4與T細(xì)胞共刺激蛋白CD28相似,兩種分子都與抗原呈遞細(xì)胞上的CD80和CD86(分別稱為B7-1和B7-2)結(jié)合。CTLA4向T細(xì)胞傳遞抑制信號(hào),而CD28則傳遞刺激信號(hào)。細(xì)胞內(nèi)CTLA4也存在于調(diào)節(jié)性T細(xì)胞中,可能對(duì)其功能很重要。CTLA4和抗體的融合蛋白(CTLA4-Ig)已用于類風(fēng)濕性關(guān)節(jié)炎的臨床試驗(yàn)。
關(guān)鍵字: CTLA-4;CTLA-4蛋白;CTLA-4重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。